Final Technical Meeting and Discussions on International R&D Projects
P483 “New Materials for Electric Drive Vehicles”
P482 "Recycling Spent Batteries for Electric Drive Vehicles"
Materials Research Centre, August 2013
| Rus | Eng |
That research projects were organized by the U.S. Department of Energy (United States Department of Energy (DoE), Argonne National Laboratory, USA, for the development of new batteries for electric drive vehicles.
Main objective of that projects is to develop and manufacture a number of experimental and new lines of experimental equipment for the development of technologies and materials for manufacturing of batteries for electric drive vehicles.
Final Technical Meeting on International R&D Project P483 “New Materials for Electric Drive Vehicles”, August 7th, 2013
Meeting of Ukrainian participants of the project P483 "New materials for electric drive vehicles" and U.S. partners was held in the MRC office and work premises on August 7th 2013. It was attended by P483 project technical monitor Dave Carter and Andrew Castiglioni (Argonne National Laboratory, USA), American partner Igor Barsukov (American Energy Technologies Company, USA), P483 project manager S.Saenko (KIPT), O. Gogotsi (Materials Research Centre), M.Gubinskyi (NMetAU), and STCU representatives- STCU’s Deputy Executive Director (USA) Vic Korsun, I.Tomashevskaya (STCU).
The participants have summed up the project P483 on manufacturing experimental equipment for pilot technological line. Also packaging and transportation and subsequent mounting in the United States have been discussed. Complex of experimental equipment designed, manufactured and assembled by MARC due to the project, was demonstrated to American party. Shown equipment is completely ready for shipment to the customer.
Technical Meeting and Discussion on International R&D Project P482 "Recycling Spent Batteries for Electric Drive Vehicles", August 8th, 2013
MRC was visited by US project manger Upendra S. Rohatgi (Brookhaven National Laboratory), Igor Barsukov (American Energy Technologies Company), Ukrainian P482 project manager M.Gubinskyi (NMetAU), S. Fedorov (NMetAU), O. Gogotsi (Materials Research Centre), V.Lutsenko (DO Yuzhnoe), Ya.Tyrygin (DO Yuzhnoe), and STCU representatives - STCU’s Deputy Executive Director from USA Vic Korsun and N.Dudko (STCU).
The workshop took place in the production of Material Research Centre, which discussed work issues on manufacturing equipment due to the project P482. At the work premises of MRC was presented developed and already manufactured, completely and partly assembled units and items of equipment for technological line.
Meeting with Expeditor on Packing and Transportation of Equipment Manufactured by MRC due to the Project P483 “New Materials for Electric Drive Vehicles”, August 28th, 2013
P 483 project collaborator Joseph Doninger (Dontech Global Inc., USA) and STCU’s Deputy Executive Director (USA) Vic Korsun visited MRC to discuss work issues on packing and shipment of completed equipment with expeditor and MRC Director O.Gogotsi.

















































MXenes potential applications include sensors, wound healing materials, and drug delivery systems. A recent study explored how different synthesis methods affect the safety and performance of MXenes. By comparing etching conditions and intercalation strategies, researchers discovered that fine-tuning the surface chemistry of MXenes plays a crucial role in improving biocompatibility. These results provide practical guidelines for developing safer MXenes and bring the field one step closer to real biomedical applications.
Exellent news, our joint patent application with Drexel University on highly porous MAX phase precursor for MXene synthesis published. Congratulations and thanks to all team involved!
Last Call! Have you submitted your abstract for IEEE NAP-2025 yet? Join us at the International Symposium on "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene-focused conference in Europe this year! Final Submission Deadline: May 15, 2025. Don’t miss this exclusive opportunity to showcase your research and engage with world leaders in the MXene field!
We are excited to announce the publication of latest review article on MXenes in Healthcare. This comprehensive review explores the groundbreaking role of MXenes—an emerging class of 2D materials—in revolutionizing the fields of medical diagnostics and therapeutics. Read the full article here: https://doi.org/10.1039/D4NR04853A.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Congratulations to all collaborators with this interesting joint work!
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.
